Fulcrum Therapeutics, Inc. financial data

Symbol
FULC on Nasdaq
Location
26 Landsdowne Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Jul 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.96K % +16.5%
Debt-to-equity 8.73 % -16.6%
Return On Equity -8.28 % +79.1%
Return On Assets -7.61 % +78.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.4M shares +0.94%
Common Stock, Shares, Outstanding 62.3M shares +19.5%
Common Stock, Value, Issued 62K USD 0%
Weighted Average Number of Shares Outstanding, Basic 62K shares +3.79%
Weighted Average Number of Shares Outstanding, Diluted 62K shares +3.79%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 74.3M USD +8.43%
General and Administrative Expense 40.1M USD -3.71%
Operating Income (Loss) -32.8M USD +69.5%
Net Income (Loss) Attributable to Parent -20.2M USD +79.4%
Earnings Per Share, Basic -0.34 USD/shares +80.7%
Earnings Per Share, Diluted -0.36 USD/shares +79.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 86.7M USD +155%
Other Assets, Current 47K USD -81.8%
Assets, Current 280M USD -0.94%
Property, Plant and Equipment, Net 4.41M USD -28.5%
Operating Lease, Right-of-Use Asset 6.36M USD -21.9%
Other Assets, Noncurrent 1.99M USD -0.3%
Assets 294M USD -2.02%
Accounts Payable, Current 3.58M USD -8.31%
Employee-related Liabilities, Current 2.72M USD -7.1%
Liabilities, Current 12.7M USD -14.2%
Operating Lease, Liability, Noncurrent 7.57M USD -21.6%
Other Liabilities, Noncurrent 197K USD -55.9%
Liabilities 20.5M USD -17.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -366K USD +69.5%
Retained Earnings (Accumulated Deficit) -481M USD -4.39%
Stockholders' Equity Attributable to Parent 274M USD -0.6%
Liabilities and Equity 294M USD -2.02%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.3M USD -4.84%
Net Cash Provided by (Used in) Financing Activities 1.65M USD -98.6%
Net Cash Provided by (Used in) Investing Activities 38.1M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 62.3M shares +0.69%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.5M USD
Deferred Tax Assets, Valuation Allowance 130M USD -21.3%
Deferred Tax Assets, Gross 133M USD -20.5%
Depreciation 1.89M USD -19.6%
Payments to Acquire Property, Plant, and Equipment 28K USD -83.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19.4M USD +80.3%
Property, Plant and Equipment, Gross 17.9M USD -0.16%
Operating Lease, Liability, Current 2.08M USD -17%
Deferred Tax Assets, Operating Loss Carryforwards 75M USD -12.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.19M USD +29.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%